Blar i forfatter "Mælandsmo, Gunhild"

Viser treff 21-27 av 27

    • Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases 

      Østrup, Olga; Dagenborg, Vegar Johansen; Rødland, Einar Andreas; Skarpeteig, Veronica; Silwal-Pandit, Laxmi; Grzyb, Krzysztof; Berstad, Audun Elnæs; Fretland, Åsmund Avdem; Mælandsmo, Gunhild; Børresen-Dale, Anne-Lise; Ree, Anne Hansen; Edwin, Bjørn; Nygaard, Vigdis; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-18)
      Background: Metastatic colorectal cancer (CRC) is associated with highly variable clinical outcome and response to therapy. The recently identified consensus molecular subtypes (CMS1-4) have prognostic and therapeutic implications in primary CRC, but whether these subtypes are valid for metastatic disease is unclear. We performed multi-level analyses of resectable CRC liver metastases (CLM) to ...

    • Nuclear Legumain Activity in Colorectal Cancer 

      Haugen, Mads Haugland; Johansen, Harald Thidemann; Pettersen, Solveig; Solberg, Rigmor; Brix, Klaudia; Flatmark, Kjersti; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)
      The cysteine protease legumain is involved in several biological and pathological processes, and the protease has been found over-expressed and associated with an invasive and metastatic phenotype in a number of solid tumors. Consequently, legumain has been proposed as a prognostic marker for certain cancers, and a potential therapeutic target. Nevertheless, details on how legumain advances ...

    • Osteopontin is a prognostic biomarker in non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Pedersen, Kjetil Boye; Øijordsbakken, Miriam; Lund-Iversen, Marius; Halvorsen, Ann Rita; Solberg, Steinar; Berge, Gisle; Helland, Åslaug; Brustugun, Odd Terje; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)
      Background: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating ...

    • Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy 

      Pedersen, Kjetil Boye; Jacob, Havjin; Frikstad, Kari-Anne; Nesland, Jahn M; Mælandsmo, Gunhild; Dahl, Olav; Nesbakken, Arild; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-06-08)
      Current clinical algorithms are unable to precisely predict which colorectal cancer patients would benefit from adjuvant chemotherapy, and there is a need for novel biomarkers to improve the selection of patients. The metastasis-promoting protein S100A4 predicts poor outcome in colorectal cancer, but whether it could be used to guide clinical decision making remains to be resolved. S100A4 exp ...

    • Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer 

      Egeland, Eivind Valen; Pedersen, Kjetil Boye; Park, Daehoon; Synnestvedt, Marit; Sauer, Torill; The Oslo Breast Cancer Consortium (OSBREAC); Naume, Bjørn; Borgen, Elin; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-01-05)
      Purpose: <br> Prognostic factors are useful in order to identify early-stage breast cancer patients who might benefit from adjuvant treatment. The metastasis-promoting protein S100A4 has previously been associated with poor prognosis in breast cancer patients. The protein is expressed in diverse subcellular compartments, including the cytoplasm, extracellular space, and nucleus. Nuclear expression ...

    • Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappa B 

      Grotterød, Ida; Mælandsmo, Gunhild; Pedersen, Kjetil Boye (Journal article; Tidsskriftartikkel; Peer reviewed, 2010)

    • Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts 

      Borgan, Eldrid; Lindholm, Evita Maria; Moestue, Siver Andreas; Mælandsmo, Gunhild; Lingjærde, Ole Christian; Gribbestad, Ingrid S; Børresen-Dale, Anne-Lise; Engebråten, Olav; Sørlie, Therese (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-10-23)
      <p>Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab.</p> <p>Two established xenograft models representing basal‐like and luminal‐like breast cancer were used to study bevacizumab ...